Healthy Clinical Trial
— BambooOfficial title:
Nutrition, Microbiome and Bone Health During Early Life Related to Health
Verified date | October 2023 |
Source | Société des Produits Nestlé (SPN) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The aim of the study is to establish the longitudinal microbiome and bone trajectories from birth to 3 years, and to evaluate the influence of nutrition on these trajectories.
Status | Active, not recruiting |
Enrollment | 2760 |
Est. completion date | December 31, 2025 |
Est. primary completion date | September 30, 2025 |
Accepts healthy volunteers | |
Gender | All |
Age group | 0 Days to 6 Months |
Eligibility | Inclusion Criteria: - It is important to carefully consider whether a subject is suitable for enrollment into this observational study. Fulfillment of the inclusion and exclusion criteria for each subject will be documented by a qualified member of the investigative staff before any subject is enrolled. Healthy infants who fulfill all the following inclusion criteria will be included: 1. Having obtained his/her parents' (or his/her legally accepted representative's [LAR's]) written informed consent and having evidence of personally signed and dated informed consent document indicating that the subject's parents/LAR have been informed of all pertinent aspects of the study. 2. Subject's parent(s)/LAR is of legal age of consent, is willing and able to fulfill the requirements of the study protocol. 3. For group 1, healthy infants aged = 10 days after birth (date of birth = Day 0). For group 2, healthy infants with maximum age of 6 months 4. Full-term gestational birth (= 37 and = 42 weeks). 5. Subject's parent(s)/LAR is able to be contacted directly by telephone throughout the study. 6. Both parents registered have a fixed work and / or residence within their jurisdiction. Exclusion Criteria: 1. Complicated pregnancy (e.g., preeclampsia, gestational diabetes, bowel disease) as assessed by medical interview/ medical record when available 2. Infant's parents/LAR not willing and/or not able to comply with scheduled visits and the requirements of the study protocol 3. Currently participating or having participated in another clinical trial within 4 weeks prior to trial start. |
Country | Name | City | State |
---|---|---|---|
China | Tianjin Women and Children Health Center, | Tianjin |
Lead Sponsor | Collaborator |
---|---|
Société des Produits Nestlé (SPN) | BGI-research, Cognizant Technology Solutions AG, SAS Institute, Tianjin Women and Children's Health Center, Veeva Systems |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | gut microbiome | microbiome maturation index derived from microbial composition, bacteria function, metabolites | Group 1: 0-1 year, Group 2: 0.5-3 years | |
Primary | dietary factors | derived from infant questionnaires | Group 1: 0-1 year, Group 2: 0.5-3 years | |
Primary | dietary factors | derived from food diaries of the types of complementary feeding, the food consumption, the nutrient intakes, the food source of nutrients, the dietary patterns | Group 1: 0-1 year, Group 2: 0.5-3 years | |
Primary | bone development | bone tibia speed of sounds (SOS) (meter / second) using ultrasound | Group 1: 0-1 year, Group 2: 0.5-3 years | |
Primary | bone health | Bone tibia length using ruler (cm) | Group 1: 0-1 year, Group 2: 0.5-3 years | |
Primary | dietary intakes and health outcomes | derived from infant questionnaires and their food diaries of the types of complementary feeding, the food consumption, the nutrient intakes, the food source of nutrients, the dietary patterns | Group 1: 0-1 year, Group 2: 0.5-3 years | |
Secondary | Gut microbiome | microbiome maturation index derived from microbial composition, bacteria function, metabolites | Group 1: 0-1 year, Group 2: 0.5-3 years | |
Secondary | Urinary markers of bone metabolism | urinary resorption biomarkers which are Pyridinolin and Deoxypiridinolin Crosslinks by ELISA | Group 1: 0-1 year, Group 2: 0.5-3 years | |
Secondary | breast milk composition | breast milk composition, macro and micronutrients (e.g. protein, mineral, etc.) | Group 1: 0-3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |